# Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

> **NCT06590857** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **RayzeBio, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Metastatic Breast Cancer
- HER2-negative Breast Cancer
- ER+ Breast Cancer
- Advanced Breast Cancer

## Interventions

- **DRUG:** RYZ101

## Key facts

- **NCT ID:** NCT06590857
- **Lead sponsor:** RayzeBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-19
- **Primary completion:** 2028-10
- **Final completion:** 2033-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06590857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06590857, "Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06590857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*